Join
Live feed
·
PRReleasevia Quantisnow
Scinai Immunotherapeutics Ltd. logo

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

ByQuantisnow·Wall Street's wire, on your screen.
SCNI· Scinai Immunotherapeutics Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SCNI (Scinai Immunotherapeutics Ltd.) and more on Quantisnow.